Healthcare Industry News: HSMN NewsFeed
News Release - May 17, 2017
Caris Life Sciences Appoints John Marshall, M.D., as Chief Medical OfficerIRVING, Texas, May 17, 2017 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences, a leading innovator in molecular science, today announced the appointment of John Marshall, M.D., as its Chief Medical Officer. Dr. Marshall will direct the company's oncology research efforts via the Caris Research Institute™ and guide clinical strategies for innovative precision medicine tools and tumor profiling services, while continuing to serve as Chairman of the Caris Centers of Excellence for Precision Medicine Network™ (COE Network) on behalf of Georgetown Lombardi Comprehensive Cancer Center.
Dr. Marshall brings more than 20 years of experience as a practicing medical oncologist and clinical trial investigator, and is Associate Director for Clinical Care for the Georgetown Lombardi and the Chief of the Division of Hematology-Oncology at MedStar Georgetown University Hospital. He is also the founding Director of Georgetown Lombardi's Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, which is dedicated to realizing the dream of individualized curative therapies through research, care and advocacy.
"As a recognized global leader and GI cancer expert, and the founding Chairman of the Caris Centers of Excellence for Precision Medicine Network initiative, John has been a strong advocate and champion for the precision oncology movement. He brings deep clinical insights that will play a key role in our ability to fulfill the promise of precision medicine," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "We are very excited to welcome John to the Caris Life Sciences team and I look forward to working more closely with him and the leadership he will bring to the company."
Dr. Marshall has been the principal investigator for more than 150 clinical trials and is widely published in journals such as the Journal of Oncology, Clinical Colorectal Cancer, Gastrointestinal Cancer Research and the Journal of Gastrointestinal Cancer. He has received numerous awards, including being named the PER® Educator of the Year for 2016.
"This is an exciting time because the precision oncology era has arrived and it is changing the cancer care landscape right now. I believe that molecular information captured from genomic and proteomic testing can dramatically improve our ability to treat patients smarter and ultimately improve outcomes," said Dr. Marshall. "I look forward to working more closely with the Caris Life Sciences team and broadening the availability of high quality, clinically useful tumor profiling services."
Under the leadership of Dr. Marshall and other members of the COE Network executive committee, the COE Network has grown to include approximately 600 physicians across more than 150 locations, and boasts five NCI-designated Comprehensive Cancer Centers. As a public/private collaboration, Network members are actively developing consensus guidelines for tumor profiling and precision medicine, while participating in research and outcomes tracking initiatives for patients that have received tumor profiling.
Dr. Marshall received his B.S. in psychology from Duke University and his M.D. from the University of Louisville School of Medicine. He completed his internal medicine residency and internship at Georgetown University Hospital and his medical oncology fellowship at Georgetown Lombardi.
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company's Comprehensive Genomic Profiling Plus (CGP+) molecular testing service and the world's leading immunotherapy diagnostic expert, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal the molecular drivers of cancer and enable the delivery of personalized medicine. The ADAPT Biotargeting System™, the company's revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.
Source: Caris Life Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsCaris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)